Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Big Is The Myocardial Infarction Market Today And What Is Its Future Size?

The market size for myocardial infarction has seen robust growth in recent years. It is projected to escalate from $2.05 billion in 2024 to $2.19 billion in 2025, presenting a compound annual growth rate (CAGR) of 6.8%. This growth during the historical period can be credited to the incorporation of beta-blockers, the establishment of chest pain clinics, thrombolytic treatments, personalized medicine strategies, and wearable cardiovascular devices.

The market for myocardial infarction is forecasted to experience substantial growth in the upcoming years, expanding to $2.92 billion in 2029 with a compound annual growth rate (CAGR) of 7.4%. The projected growth during the forecast period could be driven by worldwide health efforts towards cardiovascular health, increased availability of reperfusion therapies, RNA treatments for heart diseases, patient-oriented care models, emphasis on microvascular dysfunction, and the rise of bioelectronic medicine. The forecast period is also expected to see major trends such as developments in cardiovascular imaging, improvement in cardiac surgery methodologies, progress in telemedicine, the implementation of AI in diagnosis, the creation of digital biomarkers for risk forecasting, the application of blockchain to secure healthcare data, AI-led drug discoveries, and advancements in cardiac rehabilitation technologies.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12164&type=smp

Which Demand Drivers Are Strengthening The Myocardial Infarction Market?

The surge in the number of smokers is anticipated to fuel the expansion of the myocardial infarction market in the future. A person who smokes cigars, cigarettes, or a pipe is considered a smoker. Substances in cigarette smoke cause the blood to coagulate and clot in veins and arteries, leading to a blockage that can trigger a myocardial infarction. For example, data from the Office for National Statistics, a UK government entity, in September 2023 indicated that individuals between 25 to 34 years constituted the largest percentage of current smokers in the UK. At 16.3% or approximately 1.4 million individuals in 2022, this shows an upward trend from the preceding year, wherein the same age group had a smoking rate of 15.8%, approximately 1.3 million people. Hence, the escalating number of smokers significantly contributes to the growth of the myocardial infarction market.

Which Segment Accounts For The Largest Share In The Myocardial Infarction Market?

The myocardial infarctionmarket covered in this report is segmented –

1) By Drug Class: Antiplatelet Agents; Glycoprotein IIb Or IIIa Inhibitors; Antithrombotic Agents; Beta-Adrenergic Blockers; Vasodilators; Angiotensin-Converting Enzyme (ACE) Inhibitors; Angiotensin-Receptor Blockers; Analgesics; Thrombolytics

2) By Route Of Administration: Oral; Injectable

3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Subsegments:

1) By Antiplatelet Agents: Aspirin; Clopidogrel; Ticagrelor

2) By Glycoprotein IIb Or IIIa Inhibitors: Abciximab; Eptifibatide; Tirofiban

3) By Antithrombotic Agents: Heparins; Direct Oral Anticoagulants (DOACs)

4) By Beta-Adrenergic Blockers: Metoprolol; Carvedilol

5) By Vasodilators: Nitroglycerin; Isosorbide Dinitrate

6) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Lisinopril; Enalapril

7) By Angiotensin-Receptor Blockers: Losartan; Valsartan

8) By Analgesics: Morphine; Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

9) By Thrombolytics: Alteplase; Reteplase

What Strategic Shifts And Innovations Are Influencing The Myocardial Infarction Market?

Leading organizations within the myocardial infarction industry are concentrating their efforts on the creation of innovative drugs like anti-inflammatory medications. These drugs serve to treat targeted cardiovascular inflammation and provide a competitive advantage within the market. Anti-inflammatory drugs are those that minimize inflammation, lessening pain and swelling by directing their effects at the immune response of the body. For instance, Agepha Pharma, a medical products manufacturer based in Slovakia, obtained FDA approval in June 2023 for its drug, Lodoco (colchicine). This is the premier anti-inflammatory drug developed to tackle the root cause of atherosclerotic cardiovascular disease. Lodoco strives to decrease the incidences of myocardial infarction, stroke, coronary revascularization, and death from cardiovascular issues in adults. It can be utilized independently or in conjunction with cholesterol-reducing medications. In a clinical trial, Lodoco, a reformulated variant of low-dose colchicine, showcased an overall reduction of 31% in the risk of cardiovascular death, myocardial infarction, stroke, or coronary revascularization.

Which Companies Hold A Competitive Edge In The 323 Market?

Major companies operating in the myocardial infarction market include Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Boehringer Ingelheim GmbH, Merck KGaA, Daiichi Sankyo Co. Ltd., Apotex Inc., Siemens Healthcare Diagnostics Limited, Annexin Pharmaceuticals AB, Heartseed Inc., Par Pharmaceutical Companies Inc., Tenaya Therapeutics Inc., Idorsia Pharmaceuticals Ltd., Acesion Pharma ApS, Applied Therapeutics Inc., Athersys Inc., Cardurion Pharmaceuticals Inc., Verve Therapeutics Inc., Serca Pharmaceuticals AS

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/myocardial-infarction-global-market-report

Which Region Is Forecasted To Lead The Myocardial Infarction Market In The Coming Years?

North America was the largest region in the myocardial infarction market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the myocardial infarction market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=12164&type=smp

Browse Through More Reports Similar to the Global Myocardial Infarction Market 2025, By The Business Research Company

Legal Software Focus On Machine Learning Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/legal-software-focus-on-machine-learning-global-market-report

Legal Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/legal-services-global-market-report

B2B Legal Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/b2b-legal-services-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model